Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Atsuhiro, Kawaguchi"'
Autor:
Tong Zhu, Makoto Kayama, Sandhya Girish, Vikram Sinha, Akintunde Bello, Atsuhiro Kawaguchi, Richard Czerniak, Lee Nagao
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 1, Pp 102-105 (2021)
The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Clinical Pharmacology Leadership Group (CPLG) held its first meeting of Japan‐based representatives at Astellas Pharma headquarters in Tokyo on October 1, 20
Externí odkaz:
https://doaj.org/article/b5d6dd1914364d1fbe41af5b10015f6e
Autor:
Hiroaki Iijima, Hidetoshi Shimizu, Kazumi Mori-Anai, Atsuhiro Kawaguchi, Yoji Mochida, Toshimasa Yamauchi, Takashi Kadowaki
Teneligliptin, an antidiabetic dipeptidyl peptidase-4 inhibitor, is widely used in older patients. However, the pharmacokinetic data for teneligliptin in older people are limited. Therefore, we simulated the plasma concentration–time profiles for t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4351d3340a4d40146073fd3fe0ed9c69
https://doi.org/10.21203/rs.3.rs-2871567/v1
https://doi.org/10.21203/rs.3.rs-2871567/v1
Autor:
Lee M. Nagao, Vikram Sinha, Richard Czerniak, Makoto Kayama, Atsuhiro Kawaguchi, Sandhya Girish, Akintunde Bello, Tong Zhu
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 1, Pp 102-105 (2021)
Clinical and Translational Science, Vol 14, Iss 1, Pp 102-105 (2021)
The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Clinical Pharmacology Leadership Group (CPLG) held its first meeting of Japan‐based representatives at Astellas Pharma headquarters in Tokyo on October 1, 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a068b55e99fdd521e58a066d019195c
https://doi.org/10.1111/cts.12853
https://doi.org/10.1111/cts.12853
Autor:
Tadakatsu Nakamura, Atsuhiro Kawaguchi
Publikováno v:
Clinical Pharmacology in Drug Development
Apararenone is a long‐acting, nonsteroidal mineralocorticoid receptor antagonist (MRA). The safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single‐ and multiple‐dose apararenone were assessed in 3 phase 1 ran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf7e0d97eee550457bc907fba156240f
http://europepmc.org/articles/PMC8048531
http://europepmc.org/articles/PMC8048531
Total Ionizing Dose Effects on 28GHz CMOS Bi-Directional Transceiver for 5G Non-Terrestrial Networks
Publikováno v:
2020 20th European Conference on Radiation and Its Effects on Components and Systems (RADECS).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a52c6caa42612f810c34d095f24f7452
https://doi.org/10.1109/radecs50773.2020.9857699
https://doi.org/10.1109/radecs50773.2020.9857699
Autor:
Atsuhiro Kawaguchi, Ashbir Aviat Fadila, Dongwon You, Shunichiro Masaki, Jian Pang, Yun Wang, Kenichi Okada, Haosheng Zhang, Teruki Someya, Bangan Liu, Daisuke Yamazaki, Takeshi Nakamura, Rui Wu, Xi Fu, Kiyoshi Yanagisawa, Atsushi Shirane, Yuncheng Zhang
Publikováno v:
2020 IEEE Radio Frequency Integrated Circuits Symposium (RFIC).
This paper presents the first Ka-band satellite communication (SATCOM) transceiver in standard CMOS technology. The proposed Ka-band SATCOM transceiver is based on direct-conversion architecture with high-linearity TX and dual-channel multi-mode RX,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43def7e8e37e3f7458f392dea7d92bd6
https://doi.org/10.1109/rfic49505.2020.9218421
https://doi.org/10.1109/rfic49505.2020.9218421
Autor:
Atsuhiro Kawaguchi, Yoshinobu Nakamaru, Shuji Kinoshita, Joseph Palumbo, Koji Takei, Masayuki Suzuki
Publikováno v:
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 18:80-87
Amyotrophic lateral sclerosis (ALS) affects persons of all races, and there continues to be a need for effective therapies to treat the disease.To compare the pharmacokinetics (PK) of edaravone between Japanese and Caucasian populations.Data from fiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2d8d7b46699202e018508865ed88eb6
https://doi.org/10.1080/21678421.2017.1353100
https://doi.org/10.1080/21678421.2017.1353100
Autor:
Megumi Furukawa, Shinsuke Inoue, Stuart Mair, Takahiro Goto, Atsuhiro Kawaguchi, Takayuki Kifuji, Hiroshi Kumagai, Begonya Perez Madera
The absorption, metabolism and excretion of MT-1303 were investigated in healthy male subjects after a single oral dose of 0.4 mg [14C]-MT-1303 (ClinicalTrials.gov NCT02293967).The MT-1303 concentration in the plasma reached a maximum at 12 h after a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bca2e5a22160e4aec937dc4fc54ddf8
Autor:
Shinsuke Inoue, Tomohiko Harada, Hirotoshi Kataoka, Mahoko Asayama, Kei Ogawa, Yasuhiro Maeda, Kumiko Hikida, Atsuhiro Kawaguchi, Akira Mogami, Toshinobu Yamamoto, Hiroshi Kumagai, Kunio Sugahara, Kyoko Shimano, Pingping Ni
Publikováno v:
British Journal of Pharmacology. 174:15-27
Background and Purpose We conducted preclinical and clinical studies to examine the pharmacological, particularly cardiac, effects of amiselimod (MT-1303), a second-generation sphingosine 1-phosphate (S1P) receptor modulator, designed to reduce the b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c5957213e188b8bb2f2e40c06c08c10
https://doi.org/10.1111/bph.13641
https://doi.org/10.1111/bph.13641
Publikováno v:
Clinical Therapeutics. 42:2171-2183.e4
Purpose To characterize the clinical relevance of in vitro drug–drug interaction findings with apararenone (MT-3995), the effects of apararenone on the sensitive substrates of cytochrome P450 3A4 (midazolam) and 2C9 (warfarin), and P-glycoprotein (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f6dcce01d5c266ebf367565baec3248
https://doi.org/10.1016/j.clinthera.2020.09.002
https://doi.org/10.1016/j.clinthera.2020.09.002